Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Am J Hematol. 2020 Mar 30;95(6):662–671. doi: 10.1002/ajh.25781

FIGURE 1.

FIGURE 1

Study schema. Patients received conventional induction chemotherapy (IND1) with cytarabine (Ara–C) and idarubicin (Ida) followed by cell infusion (microtransplantation [MST]) 24–48 hours thereafter. Patients achieving a complete remission (CR) received up to 2 cycles of consolidation (CON1 and CON2) with Ara–C followed by cell infusion. Those patients not achieving a CR with IND1 could receive re–induction with the same regimen (IND2) followed by cell infusion